Details for Patent: 4,031,244
Summary for Patent: 4,031,244
| Title: | Pharmaceutical compositions containing a 1-(2,6-dimethyl-phenoxy)-2-amino-alkane and method of use | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | Pharmaceutical compositions containing as an active ingredient a compound of the formula | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Herbert Koppe, Karl Zeile, Werner Kummer, Helmut Stahle, Peter Danneberg | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Boehringer Ingelheim GmbH | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US05/653,296 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; Composition; | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | US Drug Patent 4,031,244: Scope, Claims, Expiration, and Mexiletine Patent LandscapeUS Patent 4,031,244 covers pharmaceutical compositions and therapeutic use of a class of substituted phenoxyalkylamines with anticonvulsant or antiarrhythmic activity. Its principal commercial compound is mexiletine, chemically 1-(2,6-dimethylphenoxy)-2-aminopropane, usually administered as mexiletine hydrochloride. The patent issued on June 21, 1977, and its 17-year US patent term expired on June 21, 1994. It no longer creates a US patent barrier to generic mexiletine products. The patent has two claim groups:
The claims are chemically broad at the genus level but commercially narrow in practical relevance because the patent has expired. What patent is US 4,031,244?US Patent 4,031,244 is a pre-1995 US drug patent directed to substituted phenoxyalkylamines. The patent claims pharmaceutical compositions and treatment methods using racemic or optically active compounds represented by the disclosed formula.[1]
The patent is important historically because claim 2 directly covers mexiletine in racemic or optically active form, including acceptable acid-addition salts. What compounds does US 4,031,244 cover?The independent chemical formula covers a phenoxyalkylamine framework containing:
The claimed structure is substantially broader than mexiletine alone. Claim 1 covers the genus, while claims 2 through 4 identify specific homologs. Which compounds are specifically claimed?
The patent does not claim every antiarrhythmic compound, every local anesthetic, or every phenoxyamine. The molecule must fall within the specified structural formula. How should the composition claims be interpreted?Claims 1 through 4 are pharmaceutical composition claims. They require a pharmacodynamic dosage unit composition containing:
The phrase “consisting essentially of” limits the composition more than “comprising” but less than “consisting of.” It generally permits excipients that do not materially alter the basic and novel characteristics of the claimed composition. Conventional capsule, tablet, powder, or liquid excipients would ordinarily be evaluated under that standard. The claims require a dosage-unit composition rather than merely the isolated molecule. A claim directed solely to the chemical compound would have a different scope. Here, the claimed product is a pharmaceutical dosage form containing the active compound and an inert carrier. What salt forms are covered?The claims expressly cover non-toxic, pharmacologically acceptable acid-addition salts. Mexiletine hydrochloride is the commercially relevant example. The salt language may cover salts formed with suitable inorganic or organic acids, provided the resulting salt is pharmacologically acceptable and falls within the claim. The claim does not automatically cover:
What do the method-of-use claims cover?Claims 5 through 8 cover administering the compounds to a warm-blooded animal in need of treatment. The stated therapeutic purposes are:
The claims do not specify a particular dose, route, treatment duration, disease subtype, or formulation. This gives the method claims broad therapeutic language within the boundaries of the claimed compounds and stated indications. For mexiletine, claim 6 is the direct species claim. It covers administering racemic or optically active 1-(2,6-dimethylphenoxy)-2-aminopropane, or an acceptable acid-addition salt, at an effective anticonvulsant or antiarrhythmic dose. The method claims do not cover every use of mexiletine. Uses outside convulsion suppression and cardiac-arrhythmia treatment would require separate claim analysis. The claims also do not independently establish regulatory approval for any indication. What patent protects mexiletine?US 4,031,244 is the principal patent identified from the supplied claims that directly protects mexiletine as a composition and as a treatment method. Mexiletine is the compound covered by claim 2 and the corresponding method is covered by claim 6. The patent’s protection can be summarized as follows:
When did US 4,031,244 lose exclusivity?The patent expired on June 21, 1994, based on the 17-year term applicable to US patents issued before the 1995 patent-term transition.[2] The expiration date is more than three decades in the past. No current patent-term extension or pediatric extension should be attributed to this patent. The patent predates the modern patent-term-restoration framework, and its term was governed by the pre-1995 issue-date rule.
Because the patent expired before the modern Hatch-Waxman litigation period became commercially significant for many products, current generic applicants do not need to overcome an unexpired claim in US 4,031,244. What is the FDA regulatory status of mexiletine?Mexiletine hydrochloride is an FDA-approved antiarrhythmic drug. The product is marketed in the United States in oral capsule formulations, including generic products. FDA labeling identifies mexiletine hydrochloride as a Class 1B antiarrhythmic used for documented ventricular arrhythmias, including sustained ventricular tachycardia, where treatment is considered necessary.[3] The FDA regulatory position is separate from the expired patent position. FDA approval does not revive an expired patent, and patent expiration does not eliminate the need for an approved abbreviated new drug application or other lawful regulatory pathway. Is mexiletine a biologic or a small-molecule generic?Mexiletine is a small-molecule drug. It is not a biologic and therefore does not create a biosimilar pathway under the Public Health Service Act. Generic manufacturers generally rely on the ANDA pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The relevant regulatory issues include pharmaceutical equivalence, bioequivalence, labeling, manufacturing controls, and product quality.[4] What is the Orange Book status of mexiletine?The FDA Orange Book identifies approved drug products and certain patent and exclusivity information associated with those products.[5] US 4,031,244 is expired and cannot function as a current unexpired Orange Book patent barrier. The relevant commercial conclusion is:
Are there Paragraph IV challenges to US 4,031,244?A Paragraph IV certification is used when an ANDA applicant asserts that a listed patent is invalid, unenforceable, or will not be infringed. Because US 4,031,244 expired in 1994, it is not a current Paragraph IV barrier for mexiletine products. Any historical Paragraph IV activity involving mexiletine would have concerned other listed patents, regulatory exclusivity, or product-specific patents, not the expired enforceable term of US 4,031,244. The expired patent cannot support a current 30-month stay under the Hatch-Waxman framework. What formulation patents protect mexiletine products?The supplied claims do not contain a formulation-specific invention. They require an inert pharmaceutical carrier but do not define:
The practical scope is therefore a basic dosage-unit composition. A later formulation patent could, in principle, protect a particular modified-release system, dosage form, or manufacturing process even after the core compound patent expired. Such a later patent would need its own valid priority date, written description, enablement, and non-obviousness support. No such later formulation claim is present in the eight claims supplied for US 4,031,244. Does the patent cover manufacturing methods?No. The supplied claims are directed to compositions and methods of treatment. They do not claim:
A manufacturer could still face separate process, polymorph, or trade-secret barriers under other rights. Those barriers do not arise from the claims quoted here. What is the patent litigation and settlement landscape?US 4,031,244 has no current litigation significance because its patent term expired in 1994. A claim directed to conduct occurring after expiration would generally face a fundamental term problem. The supplied record does not identify a current US infringement action, Paragraph IV case, or settlement agreement tied to this patent. Any historical litigation involving mexiletine should be separated into three categories:
Only the first category would directly bear on the scope of US 4,031,244. How strong is the patent estate for mexiletine?The historical estate was strong against direct commercial use of the claimed molecule during the patent term because claim 2 expressly named mexiletine and claim 6 expressly covered its therapeutic administration. The current estate is weak from an exclusivity perspective because the core patent is expired.
How does mexiletine compare with competing antiarrhythmics?Mexiletine competes with other antiarrhythmic drugs, including amiodarone, lidocaine, flecainide, propafenone, and sotalol. Its patent position differs from newer branded products because the core molecule has been off patent for decades.
The comparison is therapeutic, not a legal overlap analysis. A competing antiarrhythmic does not infringe US 4,031,244 merely because it has a similar mechanism or indication. The accused product would need to satisfy the patent’s structural limitations or, for a method claim, involve administration of a covered compound. What are the commercial implications for generic launch?A generic mexiletine launch does not face US 4,031,244 as an enforceable patent obstacle. The relevant commercial hurdles are instead:
There is no current royalty obligation or license requirement created solely by the expired patent. Any separate licensing obligation would have to arise from a later patent, contract, trademark, manufacturing arrangement, or other right. Key Takeaways
FAQsDoes US Patent 4,031,244 cover mexiletine hydrochloride capsules?Yes, if the capsule is a dosage-unit composition containing mexiletine hydrochloride and an inert pharmaceutical carrier. That protection expired in 1994. Is mexiletine still patent protected in the United States?US 4,031,244 no longer protects mexiletine because it expired on June 21, 1994. Separate later patents would require independent analysis. Can a generic company launch mexiletine without a license to the original patent owner?The expired patent does not require a license. The manufacturer still needs FDA approval and must avoid infringement of any separate unexpired rights. Does the patent cover mexiletine enantiomers?Yes. The claims expressly include optically active compounds. That protection also expired with the patent. Does US 4,031,244 cover extended-release mexiletine?Not specifically. The quoted claims do not recite a release mechanism, polymer system, dissolution profile, or other extended-release limitation. References
More… ↓ |
Drugs Protected by US Patent 4,031,244
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 4,031,244
International Family Members for US Patent 4,031,244
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 288353 | ⤷ Start Trial | |||
| Austria | 289075 | ⤷ Start Trial | |||
| Austria | 291225 | ⤷ Start Trial | |||
| Switzerland | 509250 | ⤷ Start Trial | |||
| Switzerland | 509251 | ⤷ Start Trial | |||
| Switzerland | 509252 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
